Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat plus azacitidine in previously untreated high-risk MDS or AML
ACTRN12610000924055Phase 2Completed
- Sponsor
- The Alfred Hospital
- Start
- Jan 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat and azacitidine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by The Alfred Hospital. Primary endpoint: Safety and tolerability. Started Jan 2010; status: completed.
02
Drugs
panobinostatazacitidine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12610000924055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000924055.